Previous 10 | Next 10 |
Gainers: LAKE +13.5% . ASPU +10.2% . CVIA +4.4% . AUPH +2.6%. BNFT +2.5% . More news on: Lakeland Industries, Inc., Aspen Group, Inc., Covia Holdings Corporation, Stocks on the move, , News on ETFs Read more ...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced ...
Introduction Corcept Therapeutics ( CORT ) is a s mall-cap ($1.43B) commercial-stage biopharmaceutical company developing innovative therapies for the treatment of oncologic, metabolic and endocrine diseases as well as psychiatric disorders. Its singular commercialized product, Korlym ...
Strongbridge Biopharma ( SBBP +3.1% ) appoints board member Richard Kollender as Chief Operating Officer effective September 3. He will resign from the board at that time. More news on: Strongbridge Biopharma plc, Healthcare stocks news, Read more ...
~ Richard S. Kollender Appointed to Chief Operating Officer ~ ~ Robert Lutz Promoted to Chief Financial Officer ~ ~ David Gill Appointed to Board of Directors ~ DUBLIN, Ireland and TREVOSE, Pa., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a g...
Strongbridge Biopharma plc (SBBP) Q2 2019 Earnings Conference Call July 31, 2019 8:30 AM ET Company Participants Lindsay Rocco – Elixir Health Public Relations Matthew Pauls – President and Chief Executive Officer Scott Wilhoit – Chief Commercial Officer Fr...
Strongbridge Biopharma (NASDAQ: SBBP ): Q2 Non-GAAP EPS of -$0.24 beats by $0.03 ; GAAP EPS of -$0.30 beats by $0.05 . More news on: Strongbridge Biopharma plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
~ KEVEYIS ® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS ® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV™ (levoketoconazole) Progre...
DUBLIN, Ireland and TREVOSE, Pa., July 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Introduction Strongbridge Biopharma ( SBBP ) is a commercial stage biopharmaceuticals company engaged in the development and commercialization of therapies for rare diseases with significant unmet needs. The company currently markets two drugs (Macrilen and Keveysis) and has another (Recor...
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...